5-Year Breast Cancer Risk Predicted Similarly in 1 vs. 2 Breast Density Measures
the Cancer Therapy Advisor take:
Two Breast Imaging Reporting and Data System (BI-RADS) density measures were found to produce similar results as a one-density model for predicting 5-year breast cancer risk in women, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants in the study included 722,654 women ranging between 35 to 74 years who completed two mammograms approximately 1.8 years apart.
The two mammograms had BI-RADS density measures and found that 13,715 of the women developed invasive breast cancer. Several factors were evaluated using Cox regression to find their relative hazards of breast cancer.
These factors included the women’s age, race/ethnicity, family history of breast cancer, breast biopsy history, and either one or two density measures.
Results showed that the two-measure density model had a slightly increased accuracy than the one-measure density model (AUC, 0.640 vs. 0.635). A specific group (15.4%) of women had their density decreased from heterogeneous or extremely dense to a lessened density with one other risk factor.
The 20,741 women had a clinically significant increase in 5-year risk with the one-measure density model compared to the two-measure density model (<1.67% to ≥1.67%, respectively).
The study suggests that a two-measure density model be considered for women whose breast density decreases when calculating breast cancer risk.
Two Breast Imaging Reporting and Data System density measures were found to produce similar results for cancer risk.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin on Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer